BridgeBio at Wells Fargo conference: growth plan centers on 2027 launches

BridgeBio said Attruby (acoramidis) annualized global revenue exceeded $1 billion in Q2 2024, including $222 million in U.S. revenue, and expects $25 million-$30 million of quarterly revenue growth through 2026. The company plans three 2027 launches—BBP-418 for limb-girdle muscular dystrophy, encaleret for ADH1 and infigratinib for achondroplasia—supported by an estimated $8 billion in de-risked post-Phase III peak sales potential and $10 billion across the pipeline. Management expects Attruby to gain toward 30%-40% ATTR-CM share as the addressable frontline market expands to at least 16,000 annual U.S. patients, though execution, competition, pricing and eventual generic tafamidis risk remain material.

Analysis

BBIO is transitioning from a single-asset commercial story to a capital-allocation story, and the equity’s next leg depends less on incremental Attruby prescriptions than on whether its sales force can support three ultra-rare launches without materially rebuilding operating expense. The commercial model is attractive where prescriber concentration is high, but patient identification—not demand—is the bottleneck for BBP-418 and encaleret; that makes genetic-testing conversion rates and time-to-treatment more relevant than peak-sales estimates. The market is likely capitalizing management’s aggregate pipeline opportunity too generously until launch pricing, payer persistence, and net revenue are independently visible.

Near term, BBIO can outperform if real-world ATTR-CM data establish clinically credible differentiation and translate into share gains versus PFE rather than simply expanding the category. The more consequential competitive read-through is for ALNY: if physicians interpret the evolving evidence as reinforcing stabilizer-first sequencing, knockdown penetration may face a ceiling in cardiomyopathy even without outright loss of patients. Conversely, PFE’s ability to use rebates and formulary positioning could compress BBIO net price before reported share gains show up in gross sales.

The contrarian risk is that the 2027 launch cluster creates a valuation air pocket: three approvals may be anticipated, but launches in fragmented, underdiagnosed populations generally ramp on diagnosis infrastructure rather than clinical enthusiasm. Infigratinib also faces the highest commercial uncertainty because switching from BMRN's established injectable franchise requires payers to recognize benefits beyond growth velocity; pediatric label scope and reimbursement criteria will matter more than oral convenience. A failure of Attruby quarterly growth to remain above the implied run-rate, or a material increase in SG&A ahead of launch, would challenge the self-funding narrative within 1-3 quarters.

Key Decisions for Investors

• Maintain BBIO as a catalyst-driven long only on a 1-3 month horizon if upcoming ATTR-CM real-world evidence produces measurable stabilization-share gains and quarterly net product revenue sustains the company’s implied sequential growth cadence. Target a 15-20% upside on multiple expansion into 2027 optionality; exit if net growth decelerates for two consecutive quarters or management raises commercial-spend guidance materially.
• Express the ATTR-CM sequencing view via a modest long BBIO / short ALNY pair through the next major cardiology-data cycle, sized beta-neutral. The thesis is relative frontline treatment mix rather than an absolute ALNY short; cover if ALNY demonstrates sustained cardiomyopathy demand acceleration or combination-treatment adoption expands.
• Do not underwrite the three 2027 launches into base-case NAV until BBIO discloses price, identified-patient conversion, and payer approval metrics. Set a watch alert for BBP-418 approval/label timing, encaleret patient-finding updates, and infigratinib reimbursement language; these data determine whether the launches deserve platform rather than single-product multiples.
• Avoid a directional PFE short solely on ATTR-CM share loss: the franchise is too small relative to PFE’s diversified earnings base. Use any PFE weakness instead as a read-through indicator of rebating intensity and formulary pressure on BBIO’s net realized price.